DDW’s Megan Thomas discusses the value of assays and their influence across the drug discovery sector. Assays are a critical part of drug discovery, providing various means to measure biological or biochemical activity of potential drug compounds. Across the sector, it is evident the impact they have and their inherent… Read More
This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More
Download the exclusive Guide and read about: What are the benefits cell line development is bringing to biopharmaceutical developers? What technological advances are helping drive efficiencies in cell line development? How is this process underpinning drug development and why is the market growing? In what ways is cell line development… Read More
John Unitt, Vice President, Immunology and Inflammation Drug Discovery, at Sygnature Discovery, explores the importance of an effective translational process for preclinical and clinical success. The global anti-inflammatory therapeutics market was estimated to be $98.26 billion in 2022 and is forecast to reach $146.14 billion by… Read More
Reece Armstrong offers an overview of cell line development and outlines the benefits the technology is bringing to biopharmaceutical developers. Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale. It is a crucial for the… Read More
DDW Editor Reece Armstrong speaks to Abraham Wang, Head of Marketing at Collaborative Drug Discovery (CDD) about annotated assays and the advantages they bring to research teams. RA: What advantages can better analysis into assays bring to drug developers? AW: Better analysis into assays offers a… Read More
In a DDW Sitting Down With podcast with Diana Spencer, Charles Powell, CEO of Aurora Microplates, discusses how microplate technology has evolved to keep up with changing trends in drug discovery and why this ubiquitous, almost invisible, tool can have a huge impact on the reliability of scientific investigations. DS:… Read More
Listen to this article on the DDW Podcast: By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was… Read More
A new collaboration aims to accelerate development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics for cachexia caused by cancer and other chronic conditions. Orbit Discovery has entered a partnership with Endevica Bio following the release of data proving that the company’s lead compound is safe and well-tolerated… Read More
This paid-for advertorial by Aurora Microplates appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 Aurora Microplates is focused on making the highest quality, highest performing microplates available. The company uses the best materials, the cleanest and most precise moulding operations and facilities to deliver high performance microplates in… Read More
This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals. … Read More
Markus Gershater, CSO and Co-Founder of Synthace discusses how technologies such as AI and automation are helping advance biotech and drug discovery. On June 5th, 1833, Charles Babbage presented a small working part of his “Difference Engine No 1” to a group of interested onlookers. Sitting in the audience was Ada… Read More
This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing… Read More
The HepGo Assay-ready 3D Liver Spheroid Kit leverages Corning Life Science’s 3D cell culture technology in liver biology and ADME/Tox. Corning has developed an all-in-one solution for the development of 3D liver models that has been designed to better recapitulate in vivo behaviour. The kit is said to deliver a… Read More
PerkinElmer is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system… Read More
The Native Antigen Company has announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit. The kit can be used to identify and qualitatively assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity. The kit contains… Read More
